These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38457593)

  • 1. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.
    Li F; Feng Q; Tao R
    Medicine (Baltimore); 2024 Mar; 103(10):e37314. PubMed ID: 38457593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning based intratumor heterogeneity signature for predicting prognosis and immunotherapy benefit in stomach adenocarcinoma.
    Chen H; Zheng Z; Yang C; Tan T; Jiang Y; Xue W
    Sci Rep; 2024 Oct; 14(1):23328. PubMed ID: 39375438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
    Deng Z; Feng Q; Zhao D; Huang Z
    Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A platelet-related signature for predicting the prognosis and immunotherapy benefit in bladder cancer based on machine learning combinations.
    Chen C; Zhang J; Liu X; Zhuang Q; Lu H; Hou J
    Transl Androl Urol; 2024 Aug; 13(8):1472-1485. PubMed ID: 39280688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning developed an intratumor heterogeneity signature for predicting clinical outcome and immunotherapy benefit in bladder cancer.
    Chen C; Zhang J; Liu X; Zhuang Q; Lu H; Hou J
    Transl Androl Urol; 2024 Jul; 13(7):1104-1117. PubMed ID: 39100839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer.
    Wang Y; Zhang Q
    Sci Rep; 2024 Oct; 14(1):22976. PubMed ID: 39363008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
    Zhang W; Wang S
    Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
    Han X; Yang L; Tian H; Ji Y
    Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Five-gene Signature based on MicroRNA for Predicting Prognosis and Immunotherapy in Stomach Adenocarcinoma.
    Wang T; Chen P; Li T; Li J; Zhao D; Meng F; Zhao Y; Zheng Z; Liu X
    Curr Med Chem; 2024; 31(17):2378-2399. PubMed ID: 38310388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma.
    Ding D; Wang L; Zhang Y; Shi K; Shen Y
    Transl Oncol; 2023 Dec; 38():101784. PubMed ID: 37722290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
    Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
    Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning developed a CD8
    Chen R; Zheng Y; Fei C; Ye J; Fei H
    Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Li Z; Guo M; Lin W; Huang P
    Arch Med Res; 2023 Nov; 54(7):102897. PubMed ID: 37865004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
    Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W
    Gene; 2022 Apr; 818():146177. PubMed ID: 35065254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel copper metabolism-related risk model to predict prognosis and tumor microenvironment of patients with stomach adenocarcinoma.
    Sun D; Zhang H; Zhang C
    Front Pharmacol; 2023; 14():1185418. PubMed ID: 37284310
    [No Abstract]   [Full Text] [Related]  

  • 17. Single-cell data revealed CD14-type and FCGR3A-type macrophages and relevant prognostic factors for predicting immunotherapy and prognosis in stomach adenocarcinoma.
    Li M; Lu M; Li J; Gui Q; Xia Y; Lu C; Shu H
    PeerJ; 2024; 12():e16776. PubMed ID: 38274323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.
    Jiang F; Lin H; Yan H; Sun X; Yang J; Dong M
    Eur J Med Res; 2022 Oct; 27(1):205. PubMed ID: 36253873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A macrophage related signature for predicting prognosis and drug sensitivity in ovarian cancer based on integrative machine learning.
    Zhao B; Pei L
    BMC Med Genomics; 2023 Oct; 16(1):230. PubMed ID: 37784081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
    Song Z; Su M; Li X; Xie J; Han F; Yao J
    BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.